JP Morgan Chase
NGNE icon

JP Morgan Chase’s Neurogene NGNE Stock Holding History

JP Morgan Chase’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.25M Buy
64,922
+59,559
+1,111% +$1.15M ﹤0.01% 4450
2025
Q4 		$110K Sell
5,363
-200
-4% -$4.98K ﹤0.01% 5832
2025
Q3 		$96.4K Sell
5,563
-772
-12% -$15.5K ﹤0.01% 5925
2025
Q2 		$94.7K Sell
6,335
-80,643
-93% -$1.27M ﹤0.01% 5631
2025
Q1 		$1.02M Sell
86,978
-394,023
-82% -$6.84M ﹤0.01% 4336
2024
Q4 		$11M Buy
481,001
+476,418
+10,395% +$17.7M ﹤0.01% 2605
2024
Q3 		$192K Buy
4,583
+184
+4% +$7.14K ﹤0.01% 5418
2024
Q2 		$160K Buy
4,399
+4,389
+43,890% +$155K ﹤0.01% 5268
2024
Q1 		$509 Hold
10
– – ﹤0.01% 6716
2023
Q4 		$194 Sell
10
-1
-9% -$14 ﹤0.01% 7052
2023
Q3 		$178 Hold
11
– – ﹤0.01% 6851
2023
Q2 		$185 Hold
11
– – ﹤0.01% 6640
2023
Q1 		$0 Sell
11
-3,637
-100% -$42.6K ﹤0.01% 7055
2022
Q4 		$37K Buy
3,648
+801
+28% +$8.27K ﹤0.01% 5713
2022
Q3 		$36K Sell
2,847
-1,429
-33% -$29.2K ﹤0.01% 5642
2022
Q2 		$88K Buy
4,276
+2,897
+210% +$70.7K ﹤0.01% 5473
2022
Q1 		$52K Sell
1,379
-7,381
-84% -$431K ﹤0.01% 5786
2021
Q4 		$845K Buy
8,760
+4,008
+84% +$488K ﹤0.01% 4506
2021
Q3 		$688K Buy
4,752
+3,939
+485% +$603K ﹤0.01% 4542
2021
Q2 		$151K Buy
813
+206
+34% +$45.6K ﹤0.01% 5375
2021
Q1 		$150K Sell
607
-119
-16% -$30.4K ﹤0.01% 5262
2020
Q4 		$205K Buy
726
+116
+19% +$28.3K ﹤0.01% 4798
2020
Q3 		$144K Buy
610
+90
+17% +$21.8K ﹤0.01% 4533
2020
Q2 		$173K Buy
520
+500
+2,500% +$130K ﹤0.01% 4327
2020
Q1 		$5K Buy
+20
New +$4.12K ﹤0.01% 5123
2019
Q3 		– Sell
-2,390
Closed -$114K – 5882
2019
Q2 		$114K Sell
2,390
-4,521
-65% -$232K ﹤0.01% 4877
2019
Q1 		$372K Sell
6,911
-2,857
-29% -$144K ﹤0.01% 4348
2018
Q4 		$422K Sell
9,768
-4,277
-30% -$208K ﹤0.01% 4221
2018
Q3 		$823K Buy
+14,045
New +$828K ﹤0.01% 4028
2018
Q2 		– Sell
-131
Closed -$37K – 5634
2018
Q1 		$37K Sell
131
-837
-86% -$231K ﹤0.01% 4911
2017
Q4 		$228K Buy
+968
New +$227K ﹤0.01% 4371
2016
Q2 		– Sell
-85
Closed -$15K – 4899
2016
Q1 		$15K Buy
+85
New +$16.5K ﹤0.01% 4157

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

JP Morgan Chase's NGNE Position: Q1 2026 in Review

JP Morgan Chase increased its Neurogene (NGNE) stake by 1,111% in Q1 2026, buying an estimated $1.15M and bringing the position to 64,922 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #4450.

JP Morgan Chase first reported a position in NGNE in Q1 2016 and has held it in 32 quarters since. The position peaked at $11M in Q4 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • JP Morgan Chase held 64,922 shares of Neurogene worth $1.25M as of Q1 2026.
  • JP Morgan Chase bought 59,559 Neurogene shares in Q1 2026, an estimated $1.15M.
  • Neurogene made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4450 holding.
  • JP Morgan Chase first reported a position in Neurogene in Q1 2016 and has held it in 32 quarters since.
  • JP Morgan Chase's Neurogene position peaked at $11M in Q4 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.